scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

3 months ago 11
Suniway Group of Companies Inc.

Upgrade to High-Speed Internet for only ₱1499/month!

Enjoy up to 100 Mbps fiber broadband, perfect for browsing, streaming, and gaming.

Visit Suniway.ph to learn

Scroll Up

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:

  • 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.
  • Leerink Partners 2025 Global Healthcare Conference: Corporate presentation on Tuesday, March 11 at 2:20PM ET.

A webcast of the presentations can be accessed here or under "News & Events” in the Investor Relations section of the Company's website, www.scPharmaceuticals.com.  

About scPharmaceuticals

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.

Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Get the latest news
delivered to your inbox

Sign up for The Manila Times newsletters

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Katherine Miranda

scPharmaceuticals Inc., 781-301-6869

[email protected]

Investors:

Nick Colangelo

Gilmartin Group, 339-225-1047

[email protected]

This website uses cookies. By continuing to browse the website, you are agreeing to our use of cookies. Read More.

Read Entire Article